The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

(2022) Wilfredo F. Garcia-Beltran et al.   CELL

Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design

(2022) Aziz Sheikh et al.   LANCET INFECTIOUS DISEASES

Evolution of antibody immunity to SARS-CoV-2

(2021) Christian Gaebler et al.   NATURE

The coronavirus proofreading exoribonuclease mediates extensive viral recombination

(2021) Jennifer Gribble et al.   PLoS Pathogens

One Year of SARS-CoV-2: How Much Has the Virus Changed?

(2021) Santiago Vilar et al.   Biology-Basel

No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants

(2021) Qianqian Li et al.   CELL

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

(2021) Piyada Supasa et al.   CELL

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

(2021) Emma C. Thomson et al.   CELL

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

(2021) Xiaoying Shen et al.   Cell Host & Microbe

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

(2021) Matthew K Hensley et al.   CLINICAL INFECTIOUS DISEASES

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

(2021) Dami A. Collier et al.   NATURE

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

(2021) Houriiyah Tegally et al.   NATURE

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) Zijun Wang et al.   NATURE

SARS-CoV-2 evolution during treatment of chronic infection

(2021) Steven A. Kemp et al.   NATURE

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

(2021) Rita E. Chen et al.   NATURE MEDICINE

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

(2021) Kai Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralizing Activity of BNT162b2-Elicited Serum

(2021) Yang Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

(2021) Nicholas G. Davies et al.   SCIENCE

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

(2021) Kevin R. McCarthy et al.   SCIENCE

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

(2021) Alexander Muik et al.   SCIENCE

Natural selection in the evolution of SARS-CoV-2 in bats created a generalist virus and highly capable human pathogen

(2021) Oscar A. MacLean et al.   PLOS BIOLOGY

Immune evasion means we need a new COVID-19 social contract

(2021) Laetitia Atlani-Duault et al.   Lancet Public Health

SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses

(2021) Benedikt Agerer et al.   Science Immunology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

(2021) Markus Hoffmann et al.   CELL

Antibody evasion by the P.1 strain of SARS-CoV-2

(2021) Wanwisa Dejnirattisai et al.   CELL

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

(2021) Venkata Viswanadh Edara et al.   Cell Host & Microbe

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

(2021) Pengfei Wang et al.   Cell Host & Microbe

Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19

(2021) Maureen Betton et al.   CLINICAL INFECTIOUS DISEASES

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

(2021) Carl Graham et al.   IMMUNITY

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination

(2021) Venkata Viswanadh Edara et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

(2021) Katherine R W Emary et al.   LANCET

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

(2021) Sandile Cele et al.   NATURE

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

(2021) Delphine Planas et al.   NATURE MEDICINE

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

(2021) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

(2021) Thandeka Moyo-Gwete et al.   NEW ENGLAND JOURNAL OF MEDICINE

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

(2021) Yang Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

(2021) Vivek Shinde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes

(2021) Lin Cheng et al.   Virology Journal

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus

(2021) Yeong Jun Kim et al.   Viruses-Basel

The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

(2021) Thomas P. Peacock et al.   Nature Microbiology

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

(2021) Elina Seppälä et al.   Eurosurveillance

A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine

(2021) Serena Messali et al.   JOURNAL OF MEDICAL VIROLOGY

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

(2021) Emma C Wall et al.   LANCET

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

(2021) Aziz Sheikh et al.   LANCET

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

(2021) Galit Alter et al.   NATURE

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

(2021) Ugur Sahin et al.   NATURE

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

(2021) Angela Choi et al.   NATURE MEDICINE

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains

(2021) Enya Qing et al.   mBio

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

(2021) Hao Zhou et al.   mBio

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

(2021) Takuya Tada et al.   mBio

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

(2021) Donal T. Skelly et al.   Nature Communications

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

(2021) Satoshi Ikegame et al.   Nature Communications

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

(2021) Bo Meng et al.   Cell Reports

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

(2021) Shaun J. Grannis et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

(2021) Daryl Geers et al.   Science Immunology

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India

(2021) Sarah Cherian et al.   Microorganisms

Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2

(2021) Katherine Laiton-Donato et al.   INFECTION GENETICS AND EVOLUTION

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2021) Elisabetta Cameroni et al.   NATURE

Evolution of enhanced innate immune evasion by SARS-CoV-2

(2021) Lucy G. Thorne et al.   NATURE

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity

(2020) Priyanka Saha et al.   BIOSCIENCE REPORTS

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

(2020) Markus Hoffmann et al.   MOLECULAR CELL

Emergence of SARS-CoV-2 through recombination and strong purifying selection

(2020) Xiaojun Li et al.   Science Advances

Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2

(2020) Saif ur Rehman et al.   Pathogens

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

(2020) Tiffany Tang et al.   ANTIVIRAL RESEARCH

Variant analysis of SARS-CoV-2 genomes

(2020) Takahiko Koyama et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

(2020) Tyler N. Starr et al.   CELL

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

(2020) Qianqian Li et al.   CELL

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

(2020) Bette Korber et al.   CELL

Distinct conformational states of SARS-CoV-2 spike protein

(2020) Yongfei Cai et al.   SCIENCE

Geographic and Genomic Distribution of SARS-CoV-2 Mutations

(2020) Daniele Mercatelli et al.   Frontiers in Microbiology

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

(2020) Maciej F. Boni et al.   Nature Microbiology

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

(2020) Leonid Yurkovetskiy et al.   CELL

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19

(2020) Benjamin J. Meckiff et al.   CELL

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

(2020) Carolyn Rydyznski Moderbacher et al.   CELL

Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection

(2020) Azadeh Rahimi et al.   GENOMICS

Spike mutation D614G alters SARS-CoV-2 fitness

(2020) Jessica A. Plante et al.   NATURE

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

(2020) Yanchun Peng et al.   NATURE IMMUNOLOGY

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

(2020) Victoria A. Avanzato et al.   CELL

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

(2020) Bina Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

(2020) Teresa Aydillo et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication

(2020) Soren Alexandersen et al.   Nature Communications

Genomic recombination events may reveal the evolution of coronavirus and the origin of SARS-CoV-2

(2020) Zhenglin Zhu et al.   Scientific Reports

Recombination events are concentrated in the spike protein region of Betacoronaviruses

(2020) Louis-Marie Bobay et al.   PLoS Genetics

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

(2016) Shuo Su et al.   TRENDS IN MICROBIOLOGY

Spread, Circulation, and Evolution of the Middle East Respiratory Syndrome Coronavirus

(2014) M. Cotten et al.   mBio

Coronaviruses

(2011) Mark R. Denison et al.   RNA Biology

Homologous Recombination Is Very Rare or Absent in Human Influenza A Virus

(2008) M. F. Boni et al.   JOURNAL OF VIROLOGY

Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice

(2008) M. M. Becker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA